Personal CFO Solutions LLC bought a new position in shares of Haleon plc (NYSE:HLN – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 12,457 shares of the company’s stock, valued at approximately $104,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HLN. Ironwood Wealth Management LLC. bought a new position in Haleon during the 3rd quarter worth about $70,000. Tower Research Capital LLC TRC bought a new position in Haleon during the 3rd quarter worth about $115,000. Credit Suisse AG bought a new stake in shares of Haleon in the 3rd quarter valued at about $76,000. Guggenheim Capital LLC bought a new stake in shares of Haleon in the 3rd quarter valued at about $119,000. Finally, BlackRock Inc. bought a new stake in shares of Haleon in the 3rd quarter valued at about $10,366,000. 6.67% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
HLN has been the subject of a number of recent research reports. Morgan Stanley started coverage on shares of Haleon in a research report on Wednesday, November 1st. They set an “overweight” rating for the company. Investec raised shares of Haleon from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy” and a consensus target price of $364.00.
Haleon Trading Up 0.1 %
Shares of NYSE HLN opened at $8.26 on Tuesday. Haleon plc has a one year low of $6.67 and a one year high of $9.05. The firm has a fifty day moving average of $8.20 and a 200 day moving average of $8.31. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.84 and a quick ratio of 0.54.
Haleon (NYSE:HLN – Get Free Report) last released its earnings results on Thursday, November 2nd. The company reported $0.10 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion for the quarter. As a group, analysts forecast that Haleon plc will post 0.44 EPS for the current fiscal year.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
- Five stocks we like better than Haleon
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- Safeguard your portfolio with these three bargain stocks
- Growth Stocks: What They Are, Examples and How to Invest
- Membership clubs gain leverage for the consumer rebound
- Election Stocks: How Elections Affect the Stock Market
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.